Profund Advisors’s Contineum Therapeutics CTNM Stock Holding History

Profund Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$508K	Buy	+37,851	New	+$564K	0.01%	564

Other funds holding CTNM

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Torren Management San Diego, California $201M AUM 16.25% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

Profund Advisors's CTNM Position: Q3 2026 in Review

Profund Advisors opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 37,851 shares worth $508K. The stake represents 0.01% of the portfolio and ranks #564 among its holdings.

15 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

Profund Advisors held 37,851 shares of Contineum Therapeutics worth $508K as of Q3 2026.
Contineum Therapeutics was a new Profund Advisors position in Q3 2026.
Contineum Therapeutics made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #564 holding.
15 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.